Pompholyx

Professional Reference articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.

See also: Pompholyx written for patients

Synonyms: dyshidrotic eczema, cheiropompholyx or cheiropompholyx and dyshidrotic dermatitis (this implies that the condition is related to sweat glands but this association is unproven)

Pompholyx comes from the Greek word for bubble.

This is a dermatitis or eczema of unknown aetiology, characterised by an itchy vesicular eruption of the hands, fingers and soles of the feet. It can be acute, recurrent or chronic and is difficult to treat effectively. It is more common in spring and summer and in countries with warmer climates. A Portuguese study found that pompholyx was the third most common type of hand eczema[2]. A French study reported a female-to-male preponderance of 1.18:1 and a mean age of 35 years[3].

The term dyshidrosis indicates a sweating abnormality but histology reveals no evidence of eccrine (sweat) gland involvement. Histologically, the vesicles are intra-epidermal with little or no inflammatory change. Hyperhidrosis is, however, an associated condition in 40% of patients and this could account for the confusion[3].

One study proposed that the aetiology involved a complex immunological process which involved complement, myeloperoxidase (a lysosomal protein stored in azurophilic granules of the neutrophil) and T cells[1]. There are a number of commonly identified aggravating factors such as emotional stress, allergic contact dermatitis and allergens such as chromate, neomycin or nickel. There is an association with atopy and tinea pedis but both pompholyx and tinea pedis are likely to occur with sweaty feet and causation is not proved. A genetic form has been identified[4]. HIV infection and treatment of HIV-infected individuals with antiretroviral therapy (ART) have both been associated, as has intravenous immunoglobulin therapy[5, 6].

Pompholyx hand

By Chalco, via Wikimedia Commons

The condition may be acute, chronic or recurrent. 80% involve the hands, 12% the feet and 8% both areas:

  • The affected areas are the centre of the palms or soles.
  • It is usually symmetrical.
  • After several hours of itching or burning in the hands, feet or both, the eruption develops. Tiny vesicles, about 1 or 2 mm in diameter, erupt, first along the lateral aspects of the fingers and then on the palms or soles.
  • Palms and soles may be red and wet with perspiration.
  • Later in the course there may be unroofed vesicles with inflamed bases, possibly accompanied by peeling or rings of scale or lichenification.
  • Transverse furrows can develop on the nail when eruptions occur in the periungual area or nail matrix.
  • Vesicles may break out in waves.
  • The vesicles usually persist for three or four weeks and disappear spontaneously.

Investigations are not usually necessary, as the diagnosis can invariably be made clinically. However, in cases which do not respond to treatment, culture and sensitivity to exclude bacterial infection, punch biopsy to exclude fungal infection and patch testing for contact dermatitis should be considered. Serology for human T-cell lymphotropic virus type 1 (HTLV-1) should also be performed to rule out dyshidrosis-like variant of adult T-cell leukaemia/lymphoma[8].

The condition is self-limiting but, as it can be intensely itchy, symptomatic treatment may be in order. In practice, many patients require a combination of treatments[10].

  • Burow's solution (10% aluminum acetate in a 1:40 dilution), is a drying soak that can be used if the lesions ooze.
  • Large blisters can be drained under aseptic conditions.
  • Antibiotics are only required if secondary infection occurs.
  • Strong topical steroids to control itching, and cold compresses (eg, a 1:10.000 solution of potassium permanganate), are the usual first-line treatment. From a practical point of view, strong topical steroids work in the 'active' phase - as the blisters are developing, Once they have dried, skin emollients with occlusion (such as plastic gloves overnight) may be useful to prevent cracking of the skin.
  • Second-line treatment may be oral steroids.
  • Long-wave PUVA (= psoralen combined with long-wave ultraviolet A) treatment has been used.
  • Severe cases may be treated with methotrexate, azathioprine, mycophenolate mofetil or ciclosporin[11, 12].
  • If nickel sensitivity has been documented, a nickel chelator such as sulfiram (Antabuse®) may be helpful[13].
  • Aluminum chloride 20% and iontophoresis may help if hyperhidrosis is a problem.
  • Botulinum A toxin has been very helpful in some patients[14].
  • Treatments currently undergoing evaluation include systemic alitretinoin (an endogenously occurring physiological vitamin A derivative)[15], topical bexarotene, leukotriene receptor antagonists, leukotriene synthesis inhibitors, phosphodiesterase-4 inhibitors and monoclonal antibodies[1].
  • The use of radiotherapy is also being explored in selected patients[10].

Secondary bacterial infection may occur. Emotional stress may have aggravated the disease and now the disease aggravates the stress.

Most patients recover spontaneously in three to four weeks but some have a chronic and unremitting course.

Did you find this information useful?

Further reading & references

  • Charlton PV; Vesico-bullous rash caused by pompholyx eczema. BMJ Case Rep. 2012 Jan 18 2012. pii: bcr1120115135. doi: 10.1136/bcr.11.2011.5135.
  1. Abreu-Velez AM, Pinto FJ Jr, Howard MS; Dyshidrotic eczema: relevance to the immune response in situ. N Am J Med Sci. 2009 Aug 1(3):117-20.
  2. Magina S, Barros MA, Ferreira JA, et al; Atopy, nickel sensitivity, occupation, and clinical patterns in different types of hand dermatitis. Am J Contact Dermat. 2003 Jun 14(2):63-8.
  3. Guillet MH, Wierzbicka E, Guillet S, et al; A 3-year causative study of pompholyx in 120 patients. Arch Dermatol. 2007 Dec 143(12):1504-8.
  4. Chen JJ, Liang YH, Zhou FS, et al; The gene for a rare autosomal dominant form of pompholyx maps to chromosome 18q22.1-18q22.3. J Invest Dermatol. 2006 Feb 126(2):300-4.
  5. MacConnachie AA, Smith CC; Pompholyx eczema as a manifestation of HIV infection, response to antiretroviral therapy. Acta Derm Venereol. 2007 87(4):378-9.
  6. Gerstenblith MR, Antony AK, Junkins-Hopkins JM, et al; Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy. J Am Acad Dermatol. 2012 Feb 66(2):312-6. doi: 10.1016/j.jaad.2010.12.034. Epub 2011 May 20.
  7. Paulsen LL, Geller DD, Guggenbiller M; Symmetrical vesicular eruption on the palms. Am Fam Physician. 2012 Apr 15 85(8):811-2.
  8. Bittencourt AL, Mota K, Oliveira RF, et al; A dyshidrosis-like variant of adult T-cell leukemia/lymphoma with clinicopathological aspects of mycosis fungoides. A case report. Am J Dermatopathol. 2009 Dec 31(8):834-7. doi: 10.1097/DAD.0b013e3181ac04fe.
  9. Wollina U; Pompholyx: what's new? Expert Opin Investig Drugs. 2008 Jun 17(6):897-904.
  10. Wollina U; Pompholyx: a review of clinical features, differential diagnosis, and management. Am J Clin Dermatol. 2010 11(5):305-14. doi: 10.2165/11533250-000000000-00000.
  11. Park H; The emergence of mycophenolate mofetilin dermatology: from its roots in the world of organ transplantation to its versatile role in the dermatology treatment room. J Clin Aesthet Dermatol. 2011 Jan 4(1):18-27.
  12. Konstantopoulou M, Belgi A, Griffiths KD, et al; Azathioprine-induced pancytopenia in a patient with pompholyx and deficiency of erythrocyte thiopurine methyltransferase. BMJ. 2005 Feb 12 330(7487):350-1.
  13. Sharma AD; Disulfiram and low nickel diet in the management of hand eczema: a clinical study. Indian J Dermatol Venereol Leprol. 2006 Mar-Apr 72(2):113-8.
  14. Forbat E, Ali FR, Al-Niaimi F; Non-cosmetic dermatological uses of botulinum neurotoxin. J Eur Acad Dermatol Venereol. 2016 Dec 30(12):2023-2029. doi: 10.1111/jdv.13772. Epub 2016 Jul 16.
  15. English J, Graham-Brown R, de Sica Chapman A, et al; Everyday clinical experience of alitretinoin in the treatment of severe chronic hand eczema: seven case studies. Clin Exp Dermatol. 2011 Mar 36 Suppl:1-2. doi:
Original Author:
Dr Richard Draper
Current Version:
Dr Nick Imm
Peer Reviewer:
Dr Laurence Knott
Document ID:
3012 (v26)
Last Checked:
15 February 2017
Next Review:
14 February 2022

Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.

Common searches for this page include: What is eczema, eczema treatment, eczema help, what causes eczema, what is pompholyx, what are pompholyx, pompholyx treatment, treatment for pompholyx, is there a cure for pompholyx, what causes pompholyx,